Thuja Capital

Alveron Pharma is developing a reversal agent for anticoagulants and platelet inhibitors to address life-threatening bleeds, initially focusing on intracranial hemorrhage. Its cyclodextrin technology accelerates but does not initiate coagulation and is designed to reverse all classes of these drugs.

Thuja backs early-stage science and supports founders developing medical breakthroughs.

Espen Eye Fund Coöperatief U.A. invests in very early-stage healthcare companies to address unmet medical needs. It promotes social characteristics but does not have sustainable investment as its objective.

The EU Life Sciences ESG Knowledge Project brings together 22 life science investors to coordinate ESG approaches in the European life science investment community. Its 2025 questionnaire is freely available to investors.

Mister MedTech and Florian discuss venture capital in BENELUX, the transition from medtech entrepreneur to VC, and emerging European medtech hubs.

Alesta’s lead asset, ALE1, is an oral therapy in development for hypophosphatasia. The financing will support development toward clinical proof of concept.

Thuja announced that EsoBiotec entered a definitive agreement to be acquired by AstraZeneca for $1 billion, including an upfront payment of $425 million. Thuja first met founder and CEO Jean-Pierre Latere in 2020.

FundaMental Pharma appointed Dr. Dirk Beher as CEO and executive board member. The neuroscience company is developing small molecule inhibitors for neurodegenerative diseases.

The page describes chronic pain as a public health problem with effects including mental health problems, fatigue, and dependence, and calls for more effective treatments with fewer side effects.

The interviewee’s responsibilities at Thuja include investor relations, marketing and communication, HR, office management, and event organization.

The interviewee describes the CEO role as isolating, with responsibility for difficult issues and no clear playbook; friends and family may not understand the challenges.

The company invests early in healthcare innovations and draws on nearly two decades of experience and a portfolio of over 30 investments to help founders navigate risks.

The company invests in biotech and medtech companies seeking to address unmet medical needs by translating science from the laboratory into the clinic.

Thuja Capital Management BV Element Offices | Bargelaan 200 2333 CW Leiden The Netherlands

The company is an early-stage venture capital firm investing in life science companies in Europe and partnering with CEOs. It draws on sector expertise, entrepreneurial experience, and a network across academia, industry, and clinical research institutions.

Thuja Capital Management B.V.’s privacy statement covers the processing of personal data about its external relations. The company says it processes this data in compliance with the Dutch Data Protection Act.

Thuja adheres to the Invest Europe Code of Conduct as a fund manager and NVP member. The code’s principles include conducting business with integrity, honesty, reliability, and professionalism.

Thuja Capital Management B.V. describes how it integrates sustainability risks into investment decisions for its third and forthcoming fourth funds.

Thuja Capital Management B.V. describes how it integrates sustainability risks into investment decisions for its third and upcoming fourth funds.

Magnolia MedTech Fund invests in very early-stage medical technology companies aiming to address unmet medical needs. The fund does not promote social characteristics or have sustainable investment as its objective.